Xiaorong Ma

483 total citations
29 papers, 359 citations indexed

About

Xiaorong Ma is a scholar working on Hematology, Oncology and Surgery. According to data from OpenAlex, Xiaorong Ma has authored 29 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 8 papers in Oncology and 7 papers in Surgery. Recurrent topics in Xiaorong Ma's work include Acute Myeloid Leukemia Research (7 papers), COVID-19 Clinical Research Studies (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Xiaorong Ma is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), COVID-19 Clinical Research Studies (5 papers) and Hematopoietic Stem Cell Transplantation (5 papers). Xiaorong Ma collaborates with scholars based in China, Macao and Pakistan. Xiaorong Ma's co-authors include Shouping Gong, Wei Jiang, Yonghong Guo, Dengfeng Gao, Fuxue Deng, Ziwei Lu, Wanggang Zhang, Yinxia Chen, Lisha Zhang and Rong Wang and has published in prestigious journals such as Molecular Immunology, Frontiers in Genetics and Aging.

In The Last Decade

Xiaorong Ma

28 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaorong Ma China 11 139 84 63 62 62 29 359
Vasiliki Vlacha Greece 8 56 0.4× 104 1.2× 36 0.6× 37 0.6× 29 0.5× 16 286
Venice Chávez‐Valencia Mexico 8 138 1.0× 128 1.5× 156 2.5× 47 0.8× 35 0.6× 18 407
Oskar Eriksson Sweden 9 111 0.8× 60 0.7× 35 0.6× 21 0.3× 122 2.0× 17 351
Amir Hamdi United States 12 25 0.2× 191 2.3× 43 0.7× 87 1.4× 73 1.2× 30 380
Georgios Trimis Greece 13 109 0.8× 47 0.6× 77 1.2× 71 1.1× 20 0.3× 25 421
K Borchert Germany 10 155 1.1× 29 0.3× 38 0.6× 174 2.8× 33 0.5× 20 542
Shinichi Morinaga Japan 10 44 0.3× 267 3.2× 22 0.3× 155 2.5× 70 1.1× 23 436
Oisín F. McElvaney Ireland 8 69 0.5× 22 0.3× 59 0.9× 29 0.5× 44 0.7× 16 295
Martin Griebel Germany 10 48 0.3× 18 0.2× 88 1.4× 56 0.9× 49 0.8× 12 476
Yoshihiko Hidaka Japan 13 35 0.3× 88 1.0× 40 0.6× 24 0.4× 235 3.8× 32 398

Countries citing papers authored by Xiaorong Ma

Since Specialization
Citations

This map shows the geographic impact of Xiaorong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaorong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaorong Ma more than expected).

Fields of papers citing papers by Xiaorong Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaorong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaorong Ma. The network helps show where Xiaorong Ma may publish in the future.

Co-authorship network of co-authors of Xiaorong Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaorong Ma. A scholar is included among the top collaborators of Xiaorong Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaorong Ma. Xiaorong Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Xiaorong, Tong‐Meng Yan, Yu Pan, & Zhi‐Hong Jiang. (2025). Optimization of siRNA therapeutics targeting MIAT for cardioprotection in myocardial ischemia/reperfusion injury. Molecular Therapy — Nucleic Acids. 36(4). 102747–102747.
2.
Liu, Jingjie, Shouping Gong, Jianrui Lv, et al.. (2023). Clinical Features and Blood Indicators for Severity and Prognosis in COVID-19 Patients. Clinical Laboratory. 69(04/2023). 2 indexed citations
3.
Zhang, Yilin, Yuxin Li, Aili He, et al.. (2023). Efficacy of recombinant human interleukin-11 in preventing and treating oral mucositis after chemotherapy for patients with acute leukemia. BMC Oral Health. 23(1). 476–476. 1 indexed citations
4.
Xu, Miao, et al.. (2022). Comprehensive Therapy for Infant Vascular Tumor Associated With Kasabach–Merritt Phenomenon—Single-Center Primary Experience. Frontiers in Pediatrics. 10. 924422–924422. 1 indexed citations
5.
Ouyang, Tianxiang, et al.. (2021). Integrated WGCNA and PPI Network to Screen Hub Genes Signatures for Infantile Hemangioma. Frontiers in Genetics. 11. 614195–614195. 21 indexed citations
6.
Liu, Hailing, Yuqiang Ji, Xiaorong Ma, et al.. (2021). Effects of CpG oligodeoxynucleotides on the differentiation of Treg/Th17 cells. Molecular Immunology. 132. 199–208. 10 indexed citations
7.
Deng, Fuxue, Lisha Zhang, Ziwei Lu, et al.. (2021). Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Medicina Clínica (English Edition). 156(7). 324–331. 41 indexed citations
8.
Deng, Fuxue, Lisha Zhang, Ziwei Lu, et al.. (2020). Increased levels of ferritin on admission predicts intensive care unit mortality in patients with COVID-19. Medicina Clínica. 156(7). 324–331. 53 indexed citations
9.
Deng, Fuxue, Dengfeng Gao, Xiaorong Ma, et al.. (2020). Corticosteroids in diabetes patients infected with COVID-19. Irish Journal of Medical Science (1971 -). 190(1). 29–31. 20 indexed citations
10.
Yang, Nan, Jinqiu Chen, Hui Zhang, et al.. (2017). Horse versus rabbit antithymocyte globulin in immunosuppressive therapy of treatment-naïve aplastic anemia: a systematic review and meta-analysis. Annals of Hematology. 96(12). 2031–2043. 19 indexed citations
11.
Shen, Ying, Aili He, Fangxia Wang, et al.. (2017). Granulocyte colony stimulating factor priming chemotherapy is more effective than standard chemotherapy as salvage therapy in relapsed acute myeloid leukemia. Medicina Clínica. 151(9). 339–344. 2 indexed citations
12.
13.
Ma, Xiaorong, Jin Wang, Wanggang Zhang, et al.. (2015). Comparison of porcine anti‐human lymphocyte globulin and rabbit anti‐human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single‐center study. European Journal Of Haematology. 96(3). 260–268. 16 indexed citations
14.
Ma, Xiaorong, Jin Wang, Wanggang Zhang, et al.. (2015). [Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].. PubMed. 23(2). 369–74. 2 indexed citations
15.
Gu, Liufang, Fangxia Wang, Xing-Mei Cao, et al.. (2010). Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 137(6). 997–1003. 21 indexed citations
16.
Chen, Yinxia, Wenping Wang, Pengyu Zhang, et al.. (2009). [Expression of genes psma6 and slc25a4 in patients with acute monocytic leukemia].. PubMed. 17(5). 1168–73. 4 indexed citations
17.
Ma, Xiaorong, Yinxia Chen, Wanggang Zhang, et al.. (2009). [Expression of co-stimulatory molecules in peripheral blood of patients with idiopathic thrombocytopenic purpura in relation with platelet antibodies].. PubMed. 17(2). 483–6. 1 indexed citations
18.
Chen, Yinxia, Xiaorong Ma, Wanggang Zhang, et al.. (2008). [Efficiency of GHA priming chemotherapy on patients with refractory acute myeloid leukemia and myelodysplastic syndrome and its relationship with expression of costimulatory molecule B7.1].. PubMed. 16(5). 1002–5. 2 indexed citations
19.
Zhang, Wanggang, Fuling Zhou, Aili He, et al.. (2006). Successful treatment of primary refractory anemia with a combination regimen of all-trans retinoic acid, calcitriol, and androgen. Leukemia Research. 30(8). 935–942. 5 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vasiliki Vlacha Breakdown of academic impact, for papers by Venice Chávez‐Valencia Breakdown of academic impact, for papers by Oskar Eriksson Breakdown of academic impact, for papers by Amir Hamdi Breakdown of academic impact, for papers by Georgios Trimis Breakdown of academic impact, for papers by K Borchert Breakdown of academic impact, for papers by Shinichi Morinaga Breakdown of academic impact, for papers by Oisín F. McElvaney Breakdown of academic impact, for papers by Martin Griebel Breakdown of academic impact, for papers by Yoshihiko Hidaka
Rankless by CCL
2026